(Q64859904)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

title

Therapeutic approaches to Huntington disease: from the bench to the clinic (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

author name string

Nicholas S Caron

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

E Ray Dorsey

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

publication date

21 September 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

23 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

page(s)

729-750

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk

23 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Trinucleotide repeat length instability and age of onset in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The Neuropathology of Huntington's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Globus pallidus degeneration and clinicopathological features of Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Orexin loss in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Symptom heterogeneity in Huntington's disease correlates with neuronal degeneration in the cerebral cortex.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Striosomes and mood dysfunction in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Cortical interneuron loss and symptom heterogeneity in Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Detection of Huntington's disease decades before diagnosis: the Predict-HD study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Longitudinal change in regional brain volumes in prodromal Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Unified Huntington's disease rating scale: Reliability and consistency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Estimating the cost of new drug development: is it really 802 million dollars?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The CREST-E study of creatine for Huntington disease: A randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Normal huntingtin function: an alternative approach to Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Protein aggregates in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

RAN Translation in Huntington Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Functional Indicators of Glutamate Transport in Single Striatal Astrocytes and the Influence of Kir4.1 in Normal and Huntington Mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin impairs immune cell migration in Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntington's Disease iPSC-Derived Brain Microvascular Endothelial Cells Reveal WNT-Mediated Angiogenic and Blood-Brain Barrier Deficits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Transcriptional dysregulation in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin facilitates polycomb repressive complex 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Dysfunctional Calcium and Glutamate Signaling in Striatal Astrocytes from Huntington's Disease Model Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Inactivation of the mouse Huntington's disease gene homolog Hdh

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin impairs vesicle formation from recycling endosomes by interfering with Rab11 activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A novel neurodevelopmental disorder associated with compound heterozygous variants in the huntingtin gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Sustained effects of nonallele-specific Huntingtin silencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Targeting several CAG expansion diseases by a single antisense oligonucleotide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Allele-specific silencing of mutant Huntington's disease gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Designing siRNA that distinguish between genes that differ by a single nucleotide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Haplotype analysis of the delta 2642 and (CAG)n polymorphisms in the Huntington's disease (HD) gene provides an explanation for an apparent 'founder' HD haplotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Ancestral differences in the distribution of the delta 2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Artificial miRNAs reduce human mutant Huntingtin throughout the striatum in a transgenic sheep model of Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Cerebrospinal Fluid Biomarkers for Huntington's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Kinase inhibitors modulate huntingtin cell localization and toxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Phosphorylation of mutant huntingtin at serine 116 modulates neuronal toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Acetylation targets mutant huntingtin to autophagosomes for degradation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Mass spectrometric identification of novel lysine acetylation sites in huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

SUMO modification of Huntingtin and Huntington's disease pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Live cell imaging and biophotonic methods reveal two types of mutant huntingtin inclusions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Phosphorylation of huntingtin at residue T3 is decreased in Huntington's disease and modulates mutant huntingtin protein conformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Multiplex genome engineering using CRISPR/Cas systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Reversal of Phenotypic Abnormalities by CRISPR/Cas9-Mediated Gene Correction in Huntington Disease Patient-Derived Induced Pluripotent Stem Cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Passage of cytokines across the blood-brain barrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Early and progressive accumulation of reactive microglia in the Huntington disease brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Microglial activation in presymptomatic Huntington's disease gene carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Distinct neuroinflammatory profile in post-mortem human Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Microglial activation correlates with severity in Huntington disease: a clinical and PET study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Neurotoxic reactive astrocytes are induced by activated microglia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Regional and cellular gene expression changes in human Huntington's disease brain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Nonclinical Safety Evaluation of VX15/2503, a Humanized IgG4 Anti-SEMA4D Antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A synaptic model of memory: long-term potentiation in the hippocampus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The functional anatomy of basal ganglia disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Location, location, location: contrasting roles of synaptic and extrasynaptic NMDA receptors in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Chronic blockade of extrasynaptic NMDA receptors ameliorates synaptic dysfunction and pro-death signaling in Huntington disease transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A pilot study of the clinical efficacy and safety of memantine for Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Chronic quinolinic acid lesions in rats closely resemble Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

One-year safety and tolerability profile of pridopidine in patients with Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

PET imaging shows loss of striatal PDE10A in patients with Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Elevated postmortem monoamine oxidase B activity in the caudate nucleus in Huntington's disease compared to schizophrenics and controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Deep Brain Stimulation in Huntington's Disease-Preliminary Evidence on Pathophysiology, Efficacy and Safety

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington's Disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Deep brain stimulation of the internal pallidum in Huntington's disease patients: clinical outcome and neuronal firing patterns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Pallidal deep brain stimulation in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Interrater agreement in the assessment of motor manifestations of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Alzheimer's disease: clinical trials and drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Diagnostic criteria for Huntington's disease based on natural history

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Prospects for neuroprotective therapies in prodromal Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A new rating scale for Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Improved metrics for Huntington’s disease trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Motor, cognitive, and functional declines contribute to a single progressive factor in early HD.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Huntington disease: natural history, biomarkers and prospects for therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Wearable Sensors in Huntington Disease: A Pilot Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Feasibility of Virtual Research Visits in Fox Trial Finder.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Novel methods and technologies for 21st-century clinical trials: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Axonal transport of adeno-associated viral vectors is serotype-dependent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Plasma testosterone in male patients with Huntington's disease: relations to severity of illness and dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Abnormal peripheral chemokine profile in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Increased frequency of diabetes mellitus in patients with Huntington's chorea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Beyond the brain: widespread pathology in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Deutetrabenazine-Not a Revolution but Welcome Evolution for Treating Chorea in Huntington Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Symptomatic treatment of Huntington disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A review of the treatment options for Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Clinical Trials Corner: September 2017.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

Neuropathological classification of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

7 January 2021

Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

7 January 2021

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

7 January 2021

Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

7 January 2021

Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

7 January 2021

A pilot study of virtual visits in Huntington disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2018.133

7 January 2021

Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-D-aspartate receptor from rat brain

1 reference

12 December 2020

Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements

1 reference

12 December 2020

Proceed with care: direct predictive testing for Huntington disease.

1 reference

12 December 2020

Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects

1 reference

12 December 2020

Flirting in little space: the ER/mitochondria Ca2+ liaison

1 reference

12 December 2020

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

1 reference

12 December 2020

Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study

1 reference

12 December 2020

Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease

1 reference

12 December 2020

In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD study

1 reference

12 December 2020

Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease

1 reference

12 December 2020

Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2018.133

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30237454%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

1 reference